Metagenomi, Inc. Common Stock (MGX) support and resistance · rev $25.2M
Metagenomi, Inc. Common Stock (MGX) is a biotechnology company listed on NASDAQ.
This page maps Metagenomi, Inc. Common Stock (MGX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.
MGX currently screens at market cap $44.4M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new MGX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the MGX quote page for the session range and the stock page for the full model.
Not investment advice.